U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C29H28N6O2.ClH.H2O
Molecular Weight 547.048
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TEPOTINIB HYDROCHLORIDE

SMILES

O.Cl.CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1

InChI

InChIKey=KZVOMLRKFJUTLK-UHFFFAOYSA-N
InChI=1S/C29H28N6O2.ClH.H2O/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30;;/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3;1H;1H2

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25736998 https://www.ncbi.nlm.nih.gov/pubmed/23553846

Tepotinib is an investigational small molecule inhibitor of the c-Met receptor tyrosine kinase. Alterations of the c-Met signaling pathway are found in various cancer types and correlate with aggressive tumor behavior and poor clinical prognosis. Tepotinib is a potent and selective c-Met inhibitor, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib is currently in Phase I/II trials in liver cancer and lung cancer.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
2013 Jun 1
Patents

Sample Use Guides

500 mg of tepotinib tablet once daily orally during each 21 day cycle
Route of Administration: Oral
Tepotinib inhibits HGF-induced c-Met phosphorylation in A549 cells with IC50 of 6 nM. Treatment with Tepotinib induces a marked reduction of c-Met–constitutive phosphorylation in EBC-1 cells with IC50 of 9 nM. Tepotinib effectively blocks phosphorylation of the major downstream effectors of the c-Met enzyme, such as Grb2, Gab1, Sos, PLCγ, and phosphoinositide 3-kinase, in EBC-1, MKN-45, and Hs746T cells in the range of 1 to 10 nM.
Name Type Language
TEPOTINIB HYDROCHLORIDE
USAN  
Official Name English
MSC2156119J
Code English
TEPOTINIB HYDROCHLORIDE MONOHYDRATE
Common Name English
TEPOTINIB HYDROCHLORIDE HYDRATE [JAN]
Common Name English
TEPMETKO
Brand Name English
TEPOTINIB HYDROCHLORIDE [USAN]
Common Name English
TEPOTINIB HYDROCHLORIDE [ORANGE BOOK]
Common Name English
BENZONITRILE, 3-(1,6-DIHYDRO-1-((3-(5-((1-METHYL-4-PIPERIDINYL)METHOXY)-2-PYRIMIDINYL)PHENYL)METHYL)-6-OXO-3-PYRIDAZINYL)-, HYDROCHLORIDE, HYDRATE
Systematic Name English
BENZONITRILE, 3-(1,6-DIHYDRO-1-((3-(5-((1-METHYL-4-PIPERIDINYL)METHOXY)-2-PYRIMIDINYL)PHENYL)METHYL)-6-OXO-3-PYRIDAZINYL)-, HYDROCHLORIDE, HYDRATE (1:1:1)
Systematic Name English
Tepotinib hydrochloride monohydrate [WHO-DD]
Common Name English
Code System Code Type Description
FDA UNII
VY5YX2TQ1F
Created by admin on Sat Dec 16 14:18:42 GMT 2023 , Edited by admin on Sat Dec 16 14:18:42 GMT 2023
PRIMARY
CAS
1234780-14-3
Created by admin on Sat Dec 16 14:18:42 GMT 2023 , Edited by admin on Sat Dec 16 14:18:42 GMT 2023
NON-SPECIFIC STOICHIOMETRY
CAS
1946826-82-9
Created by admin on Sat Dec 16 14:18:42 GMT 2023 , Edited by admin on Sat Dec 16 14:18:42 GMT 2023
PRIMARY
SMS_ID
300000011280
Created by admin on Sat Dec 16 14:18:42 GMT 2023 , Edited by admin on Sat Dec 16 14:18:42 GMT 2023
PRIMARY
NCI_THESAURUS
C171761
Created by admin on Sat Dec 16 14:18:42 GMT 2023 , Edited by admin on Sat Dec 16 14:18:42 GMT 2023
PRIMARY
USAN
HI-33
Created by admin on Sat Dec 16 14:18:42 GMT 2023 , Edited by admin on Sat Dec 16 14:18:42 GMT 2023
PRIMARY
RXCUI
2477104
Created by admin on Sat Dec 16 14:18:42 GMT 2023 , Edited by admin on Sat Dec 16 14:18:42 GMT 2023
PRIMARY
CAS
1100598-30-8
Created by admin on Sat Dec 16 14:18:42 GMT 2023 , Edited by admin on Sat Dec 16 14:18:42 GMT 2023
NON-SPECIFIC STOICHIOMETRY
PUBCHEM
46700774
Created by admin on Sat Dec 16 14:18:42 GMT 2023 , Edited by admin on Sat Dec 16 14:18:42 GMT 2023
PRIMARY
DAILYMED
VY5YX2TQ1F
Created by admin on Sat Dec 16 14:18:42 GMT 2023 , Edited by admin on Sat Dec 16 14:18:42 GMT 2023
PRIMARY